Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Gilead Sciences Inc (NASDAQ: GILD)

$65.93 USD -$0.57 (-0.86%)
Last Price $65.93
Net Change $-0.57 (-0.86%)
Bid $66.5
Ask Price $66.66
Open Price $66.54
Previous Close Price $66.5
High Price $66.68
Low Price $65.75
Number of Trades 12
Volume 7,241,400
Fifty Two Week High $103.1 (2016-04-26)
Fifty Two Week Low $65.38 (2017-02-09)
Average Daily Volume 9,862,336
Share Outstanding 1,307,240 Shares
Total Dividend Payout 2.08/yr
Dividend Yield 3.13%
1st Quarter Earnings $2.7 (2017-02-07)
2nd Quarter Earnings $2.75 (2016-11-01)
3nd Quarter Earnings $3.08 (2016-07-25)
4th Quarter Earnings $3.03 (2016-04-28)
PE Ratio $5.86
EPS Growth $-29.2
Recent Earnings $2.7
Annual EPS $11.35
Last Quarter EPS $
Market Capitalization $86.19B
Insider Shareholders % 0.013%
Annual Revenue $0B
No. Shares Outstanding 1,307,240
Inst. Shareholder % 75.54%
Annual Net Income $0B
TTM Net Profit Margin $-0.51
1-Year Return -33.63%
3-Year Return -6.87%
5-Year Return 167.57%
5-Year Revenue Growth 262.42%
5-Year Earnings Growth 521.31%
5-Year Dividend Growth 0%
Annual Dividend $2.08
Annual Dividend Yield 3.13%
Change in EPS YTD -29.200001%
Dividends per Share $0.52
Stock Split Ratio 2-1
Beta 1.14
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.

Today's Gilead Sciences Stock Update

While we usually like to analyze for investors whether a stock is a buy or not, we also like to give you a quick rundown of the Gilead Sciences stock information you need today, with key data on recent GILD moves. That's what you can get right here. Let's start with the last closing price for GILD stock, which was $65.93. Gilead Sciences shares fell 0.86% or $0.57 from the day before. Looking at the 52-week highs and lows for GILD is a good way to make sense of the current price, so let's do that now... Gilead Sciences is currently trading at a lower price than it was one-year ago, with shares having slipped 35.20% from then.

BREAKING: How a 26(f) Program Can Save Your Retirement

The Gilead Sciences stock price 52-week high is $103.10. That was hit on 4/26/2016. The GILD stock 52-week low is $65.38, reached on 2/09/2017. Another number to look at - GILD trading volume yesterday was 6,380,400. That's not quite as high as Gilead Sciences stock's average daily trading volume of 7,241,809. Gilead Sciences's market cap is 86,186,333,000. That gives Gilead Sciences a large market cap, because it's between 10 billion and 200 billion. As of the beginning of April, Apple has the biggest market cap of all publicly traded companies.

TRENDING: The Best Stocks to Buy Now

The current P/E (price/earnings) ratio of Gilead Sciences stock is 5.86. That's lower than the March 2016 S&P 500 P/E ratio of about 23. To really gauge if this stock's P/E is high or low, you should compare GILD to other companies in the same industry. The current EPS (earnings per share) of GILD is 9.94. Beta - how closely the stock trades with the overall market, with a beta of 1 meaning it trades in step with the broader index -- for Gilead Sciences is 1.14. Gilead Sciences stock has a dividend yield of 3.13%. Generally a dividend yield of 2% or more is decent for those investors who want income from dividend stocks. For more info on Gilead Sciences stock, check out all the free content we give you at Money Morning. You'll find GILD stock news and coverage on dozens of other key stocks, updated daily.

UP NEXT: These Are the Top 5 Marijuana Stocks to Watch in 2017 - Don't Miss This Sector's Staggering Profit Potential

Click here to read more stories